Study Title and Description
Comparison of commercial molecular assays for toxigenic Clostridium difficile detection in stools: BD GeneOhm Cdiff, XPert C. difficile and illumigene C. difficile.
Key Questions Addressed
|1||How do different methods for detection of toxigenic C. difficile to assist with diagnosis of CDI compare in their sensitivity, specificity, and predictive values? a. Overall? b. Do performance measures vary with sample characteristics? c. Does testing strategy impact patient health or health system outcomes?|
|2||What are effective prevention strategies? a. What is the effectiveness of current prevention strategies? b. What are the harms associated with prevention strategies? c. How sustainable are prevention practices in health care (outpatient, hospital inpatient, extended care) and community settings?|
|3||What is the comparative effectiveness and harms of different antibiotic treatments? a. Does effectiveness vary by disease severity?|
|4||What are the effectiveness and harms of other interventions? a. Overall b. In patients with relapse/recurrent CDI.|
Primary Publication Information
|Title||Comparison of commercial molecular assays for toxigenic Clostridium difficile detection in stools: BD GeneOhm Cdiff, XPert C. difficile and illumigene C. difficile.|
|Author||Viala C., Le Monnier A., Maataoui N., Rousseau C., Collignon A., Poilane I.|
|Country||Laboratoire de Microbiologie, Hôpital Jean Verdier, Assistance Publique - Hôpitaux de Paris, Bondy, France.|
Pubmed ID: 22565213
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Detection, prevention, treatments, and efficacy and harms of interventions for C. difficile
Results & Comparisons
No Results found.